Have a feature idea you'd love to see implemented?
Let us know!
LBPH Longboard Pharmaceuticals Inc
Price (delayed)
$59.57
Market cap
$2.32B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.15
Enterprise value
$2.31B
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard was formed in January 2020 by Arena to advance a portfolio of
Highlights
The EPS is up by 16% year-on-year and by 4% since the previous quarter
The company's debt fell by 3% QoQ
The quick ratio has soared by 159% YoY but it has contracted by 34% from the previous quarter
The net income is down by 31% year-on-year and by 12% since the previous quarter
The equity has contracted by 6% from the previous quarter
Key stats
What are the main financial stats of LBPH
Market
Valuations
Earnings
Shares outstanding
38.9M
Market cap
$2.32B
Enterprise value
$2.31B
Price to earnings (P/E)
N/A
Price to book (P/B)
7.86
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$64.74M
EBITDA
-$64.73M
Free cash flow
-$58.63M
Per share
Balance sheet
Liquidity
EPS
-$2.15
Free cash flow per share
-$1.51
Book value per share
$7.58
Revenue per share
$0
TBVPS
$8.05
Total assets
$312.91M
Total liabilities
$18.31M
Debt
$3.86M
Equity
$294.6M
Working capital
$294.07M
Debt to equity
0.01
Current ratio
20.95
Quick ratio
20.69
Net debt/EBITDA
0.17
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-34.5%
Return on equity
-36.9%
Return on invested capital
-42.4%
Return on capital employed
-21.7%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LBPH stock price
How has the Longboard Pharmaceuticals stock price performed over time
Intraday
0.03%
1 week
0.68%
1 month
82.39%
1 year
1,052.22%
YTD
887.89%
QTD
78.73%
Financial performance
How have Longboard Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$72.96M
Net income
-$64.74M
Gross margin
N/A
Net margin
N/A
Longboard Pharmaceuticals's operating income has decreased by 42% YoY and by 16% from the previous quarter
The net income is down by 31% year-on-year and by 12% since the previous quarter
Growth
What is Longboard Pharmaceuticals's growth rate over time
Valuation
What is Longboard Pharmaceuticals stock price valuation
P/E
N/A
P/B
7.86
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is up by 16% year-on-year and by 4% since the previous quarter
The P/B is 162% above the last 4 quarters average of 3.0
The equity has contracted by 6% from the previous quarter
Efficiency
How efficient is Longboard Pharmaceuticals business performance
The ROIC has soared by 58% YoY and by 34% from the previous quarter
LBPH's return on equity has surged by 51% year-on-year and by 26% since the previous quarter
The ROA has grown by 48% YoY and by 25% from the previous quarter
Dividends
What is LBPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LBPH.
Financial health
How did Longboard Pharmaceuticals financials performed over time
The quick ratio has soared by 159% YoY but it has contracted by 34% from the previous quarter
Longboard Pharmaceuticals's current ratio has surged by 152% YoY but it has decreased by 33% QoQ
The company's debt is 99% lower than its equity
The equity has contracted by 6% from the previous quarter
The company's debt fell by 3% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.